Topics
8 signals
Centene Corp. continues to be a leading contractor in managing Medicaid, Medicare, and ACA programs. Procurement professionals should monitor changes in Medicaid eligibility and state contracts that could impact managed care organizations.
CMS has introduced the **Medicare GLP-1 Bridge** program to provide access to select GLP-1 medications for **$50 per month** for eligible beneficiaries through **December 31, 2027**. This innovative initiative aims to enhance weight management treatment and could influence future procurement opportunities within the pharmaceutical industry, especially concerning Medicare Part D.
The Centers for Medicare & Medicaid Services (CMS) is proposing significant updates for Medicare program integrity. These changes include enhanced fraud prevention, expanded home health care access, and revised payment structures, impacting providers and contractors in the Medicare space.
CMS seeks public input through an RFI on Pharmacy Benefit Manager (PBM) reforms under Medicare Part D, effective January 1, 2028. Stakeholders must consider how these changes will impact PBM compensation and the overall landscape of pharmacy services, as the Medicare Drug Price Negotiation Program advances alongside these reforms.
The Centers for Medicare & Medicaid Services (CMS) has introduced a permanent rule for Medicare drug price negotiations that begins in 2029. This foundational regulation aims to reduce drug prices for Medicare beneficiaries, create compliance mandates for Part D plans, and foster innovation in the pharmaceutical sector, particularly for small biotech firms.
An audit from HHS OIG has identified significant improper Medicare payments for telehealth services. The report emphasizes the need for CMS to enhance billing guidance and implement better oversight through targeted system edits to mitigate errors and improve accuracy in claims processing.
The Centers for Medicare & Medicaid Services has enacted a six-month moratorium on new Medicare enrollments for hospice and home health agencies. This action aims to combat fraud and reinforce integrity within the Medicare system, which could significantly affect market dynamics and compliance requirements for contractors in these sectors.
Beginning July 1, 2026, CMS will offer Medicare Part D beneficiaries access to GLP-1 medications for $50 monthly. This initiative is set to enhance affordable healthcare solutions and may impact pharmaceutical procurement strategies significantly.